NEUP earnings: next report 2026-09-02, real EPS beat/miss history, analyst consensus Buy, P/E -0.30. Updated 2026-07-23.
Neuphoria Therapeutics (NEUP) Research Hub
Neuphoria Therapeutics (NEUP) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 3.73 USD (-0.53%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.30, market cap 0.02B. This hub links to the full technical, earnings and options research available for NEUP.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.73 USD (-0.53%) |
| 52-week range | 3.28 USD – 4.64 USD |
| Trend regime | Range |
| 14-day RSI | 39 (Bearish) |
| Trailing P/E | -0.30 |
| Market cap | 0.02B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-02 |
Available research for NEUP
Covered Call on NEUP: how it works, illustrative setup around the real 3.73 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on NEUP: how it works, illustrative setup around the real 3.73 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on NEUP: how it works, illustrative setup around the real 3.73 USD price, max profit/loss, breakeven and when to use it. Educational.
NEUP technical analysis: range, last 3.73 USD, RSI 39, 52w range 3.28 USD–4.64 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is NEUP in?
Neuphoria Therapeutics (NEUP) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is NEUP in an uptrend or downtrend?
As of 2026-09-11, NEUP is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is NEUP's trailing P/E ratio?
NEUP's trailing P/E is -0.30, with a market cap of 0.02B. See the earnings research page for full valuation detail.
When does NEUP next report earnings?
NEUP is next scheduled to report earnings on 2026-09-02, with a consensus EPS estimate of -0.56 USD.